Compositions and methods of treating retinal disease
US-9650342-B2 · May 16, 2017 · US
Compositions and methods of treating retinal disease
US11724987B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11724987-B2 |
| Application number | US-202117164556-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2021 |
| Priority date | May 26, 2005 |
| Publication date | Aug 15, 2023 |
| Grant date | Aug 15, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
First claim
Opening claim text (preview).
We claim: 1. A method of treating macular degeneration in a subject, the method comprising administering to the subject a compound of the following structure: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the macular degeneration is age related macular degeneration (AMD). 3. The method of claim 2 , wherein the AMD is wet AMD. 4. The method of claim 2 , wherein the AMD is dry AMD. 5. The method of claim 1 , wherein the macular degeneration is Stargardt's disease. 6. The method of claim 1 , wherein the compound is administered topically to the eye of the subject. 7. The method of claim 1 , wherein the compound is administered as an eye-drop or ophthalmic ointment. 8. The method of claim 1 , wherein the compound is administered by intraocular injection. 9. The method of claim 8 , wherein the compound is
Assignees
Inventors
Classifications
- C07D215/38Primary
Nitrogen atoms (nitro radicals C07D215/18) · CPC title
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title
condensed with carbocyclic rings · CPC title
1,3-Thiazoles · CPC title
having six-membered rings with one nitrogen as the only ring hetero atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11724987B2 cover?
- Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
- Who is the assignee on this patent?
- Aldeyra Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D215/38. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).